Related Experiment Video
Updated: May 26, 2026
07:30
Transcanalicular Diode Laser-assisted Dacryocystorhinostomy for the Treatment of Primary Acquired Nasolacrimal Duct Obstruction
Published on: October 13, 2017
Mitomycin C in revision endoscopic dacryocystorhinostomy: a prospective randomized study
Elina Penttilä1, Grigori Smirnov, Juha Seppä
1Department of Otorhinolaryngology, Institute of Clinical Medicine, Kuopio University Hospital, and University of Eastern Finland, Finland.
American Journal of Rhinology & Allergy
|December 22, 2011
Summary
Intraoperative mitomycin C (MMC) may improve outcomes for revision endoscopic dacryocystorhinostomy (EN-DCR) surgery. While not statistically significant, MMC use showed a higher success rate and significant symptom relief in patients with nasolacrimal duct obstruction.
Area of Science:
- Ophthalmology
- Otorhinolaryngology
Background:
- Endoscopic dacryocystorhinostomy (EN-DCR) treats nasolacrimal duct obstruction.
- Scarring can complicate revision EN-DCR procedures.
- Mitomycin C (MMC) is an antiproliferative agent explored to reduce fibrosis.
Purpose of the Study:
- To evaluate the efficacy of intraoperative mitomycin C (MMC) in improving success rates for revision endoscopic dacryocystorhinostomy (EN-DCR).
Main Methods:
- A prospective, randomized study of 30 revision EN-DCR procedures.
- Patients were randomized into two groups: MMC application or no MMC.
- Success defined by lacrimal sac irrigation and symptom relief at 6 months.
Main Results:
- Revision EN-DCR with MMC achieved a 93% success rate versus 60% without MMC.
- Symptom relief was statistically significant in the MMC group (p=0.007 for NLDO score, p=0.02 for ocular symptoms).
- The overall difference in success rate between groups was not statistically significant (p=0.08).
Conclusions:
- Intraoperative mitomycin C shows potential to enhance outcomes in revision EN-DCR.
- MMC application may lead to better symptom resolution in patients undergoing revision EN-DCR for nasolacrimal duct obstruction.